Primary Generalized Tonic Clonic Seizures clinical trials

Explore recruiting primary generalized tonic clonic seizures clinical trials.

Recruiting primary generalized tonic clonic seizures studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Primary Generalized Tonic Clonic Seizures trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Open Label Extension Clinical Trial of Vormatrigine in Adult Patients with Epilepsy.

Germany, Spain, Poland, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter Open-label Extension Study to Evaluate the Long-term Safety of Cenobamate Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures

Germany, Hungary, Spain, Slovakia, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures

Slovakia, Hungary, Spain, Poland, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures (X-ACKT)

Portugal, Spain, Italy, Austria, Czechia, Poland +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients with Focal Onset or Primary Generalized Tonic-Clonic Seizures

Germany, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Subjects Diagnosed With Epilepsy (X-TOLE4)

Spain, Portugal, Czechia, Hungary, Poland, Italy +10 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Primary Generalized Tonic Clonic Seizures trials by city

Primary Generalized Tonic Clonic Seizures in Toronto Primary Generalized Tonic Clonic Seizures in Vancouver Primary Generalized Tonic Clonic Seizures in Montreal Primary Generalized Tonic Clonic Seizures in Calgary Primary Generalized Tonic Clonic Seizures in Edmonton Primary Generalized Tonic Clonic Seizures in Ottawa Primary Generalized Tonic Clonic Seizures in Winnipeg Primary Generalized Tonic Clonic Seizures in Quebec City Primary Generalized Tonic Clonic Seizures in Hamilton Primary Generalized Tonic Clonic Seizures in Kitchener Primary Generalized Tonic Clonic Seizures in London Primary Generalized Tonic Clonic Seizures in Halifax Primary Generalized Tonic Clonic Seizures in New York Primary Generalized Tonic Clonic Seizures in Los Angeles Primary Generalized Tonic Clonic Seizures in Chicago Primary Generalized Tonic Clonic Seizures in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease